Report: Smaller, Established Pot Stocks Key to Profits in 2021
Cannabis investors have been burned in the past by big name companies that saw their stock values skyrocket overnight, only to plummet back to earth when the challenge of turning a profit proved too difficult. Experts say key to making money with cannabis stocks is to invest in smaller companies with a track record of success.
Find Out Why This Seattle Company Could Be the #1
Kevin Lee, insider at Bicycle Therapeutics
Kevin Lee Insider Alerts

Get notified the next time Kevin Lee buys or sells Bicycle Therapeutics stock. Enter your email address below to get our daily insider buying and selling report.

Kevin Lee Insider Information

Kevin joined Bicycle Therapeutics from Pfizer, where he served as senior vice president and chief scientific officer of the Rare Disease Research Unit. In that role, he held responsibility for more than 20 novel programs across the full spectrum of research and development, established Pfizer’s rare disease strategy, conceptualized and implemented the company’s gene therapy strategy with the creation of the Genetic Medicine Institute and founded the Rare Disease Research Consortium. Prior to joining Pfizer, Kevin worked at GlaxoSmithKline (GSK) and, in addition to leading the formation of multiple strategic commercial and academic partnerships, he led epigenetics research and was responsible for the creation of the EpiNova Discovery Performance Unit. Before joining GSK, he lectured at Warwick University Medical School and founded Cambridge Biotechnology (acquired by Biovitrum) and Neurosolutions.

Kevin studied pharmaceutical sciences at Nottingham University, followed by a Ph.D. in pharmacology at Cambridge University. He undertook postdoctoral training as a Wellcome Trust International Prize Fellow before joining the Parke Davis Research Unit in Cambridge, U.K. Kevin is an author on over 100 peer-reviewed scientific publications, has an MBA from Warwick Business School and has been awarded an honorary Chair in Molecular Pharmacology from the University of Warwick. In addition to his seat on Bicycle’s board of directors, Kevin is also a non-executive director of NodThera Ltd.

What is Kevin Lee's net worth?

The estimated net worth of Kevin Lee is at least $13.65 million as of August 27th, 2021. Dr. Lee owns 246,893 shares of Bicycle Therapeutics stock worth more than $13,648,245 as of October 22nd. This net worth estimate does not reflect any other investments that Dr. Lee may own. Learn More.

What is Kevin Lee's salary?

As the CEO of Bicycle Therapeutics plc, Dr. Lee earned a total compensation package of $2,506,749.00 in 2020. Dr. Lee earned a salary of $592,250.00, options awards of $1,349,965.00, non-equity compensation of $501,361.00, and other compensation of $63,173.00.

How do I contact Kevin Lee?

The corporate mailing address for Dr. Lee and other Bicycle Therapeutics executives is B900 BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0, CB22 3AT. Bicycle Therapeutics can also be reached via phone at 441223261503.

Has Kevin Lee been buying or selling shares of Bicycle Therapeutics?

During the last ninety days, Kevin Lee has sold $550,200.00 in shares of Bicycle Therapeutics stock. Most recently, Kevin Lee sold 49 shares of the business's stock in a transaction on Monday, October 18th. The shares were sold at an average price of $60.00, for a transaction totalling $2,940.00.

Who are Bicycle Therapeutics' active insiders?

Bicycle Therapeutics' insider roster includes Stephen Alexander (SVP), Kate Bingham (Director), Nigel Crockett (Insider), Lee Kalowski (CFO), Nicholas Keen (Insider), Kevin Lee (CEO), and Pierre Legault (Director).

Are insiders buying or selling shares of Bicycle Therapeutics?

In the last twelve months, insiders at the sold shares 36 times. They sold a total of 370,765 shares worth mmore than $11,623,870.06. The most recent insider tranaction occured on October, 18th when Kevin Lee CEO bought 49 shares worth more than $2,940.00. Insiders at Bicycle Therapeutics own 17.9 % of the company.

Information on this page was last updated on 10/18/2021.

Kevin Lee Insider Trading History at Bicycle Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/18/2021Sell49$60.00$2,940.00View SEC Filing Icon  
10/14/2021Sell4,631$60.00$277,860.00View SEC Filing Icon  
10/11/2021Sell5,000$53.88$269,400.00View SEC Filing Icon  
8/31/2021Sell11,225$36.33$407,804.25View SEC Filing Icon  
8/27/2021Sell1,808$36.02$65,124.16246,893View SEC Filing Icon  
7/26/2021Sell100$36.00$3,600.00View SEC Filing Icon  
7/23/2021Sell4,782$36.02$172,247.64View SEC Filing Icon  
7/16/2021Sell609$34.00$20,706.00View SEC Filing Icon  
7/14/2021Sell14,465$34.34$496,728.10256,670View SEC Filing Icon  
7/12/2021Sell1,936$32.04$62,029.44View SEC Filing Icon  
5/6/2021Sell1,716$32.14$55,152.24256,450View SEC Filing Icon  
5/4/2021Sell897$32.03$28,730.91258,125View SEC Filing Icon  
4/30/2021Sell58,919$30.86$1,818,240.34277,229View SEC Filing Icon  
4/28/2021Sell22,495$31.08$699,144.60277,229View SEC Filing Icon  
4/26/2021Sell18,611$31.28$582,152.08273,345View SEC Filing Icon  
1/19/2021Sell5,000$29.26$146,300.00260,556View SEC Filing Icon  
1/15/2021Sell10,000$26.01$260,100.00270,085View SEC Filing Icon  
See Full Table

Kevin Lee Buying and Selling Activity at Bicycle Therapeutics

This chart shows Kevin Lee's buying and selling at Bicycle Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Bicycle Therapeutics Company Overview

Bicycle Therapeutics logo
Bicycle Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in developing a novel class of medicines, which the company refers to as bicycles, for diseases that are underserved by existing therapeutics. The firm utilizes its novel and proprietary phage display screening platform to identify bicycles. Its portfolio includes internal product candidates that are directed to oncology applications. The company was founded by Gregory Winter, John Tite, and Christian Heinis in 2009 and is headquartered in Cambridge, the United Kingdom.
Read More

Today's Range

Now: $55.28
Low: $53.84
High: $55.39

50 Day Range

MA: $40.46
Low: $27.95
High: $59.65

2 Week Range

Now: $55.28
Low: $17.68
High: $60.34


3,835 shs

Average Volume

610,158 shs

Market Capitalization

$1.41 billion

P/E Ratio


Dividend Yield



How This Rare Metal Is Going To Solve A $173 TRILLION World Problem… And Could Benefit Investors
According to Bloomberg NEF, changing the world to "All Green Energy" could cost about $173 trillion. And without this rare metal, going green would be IMPOSSIBLE. That's why there's a literal "gold rush" to find it. (HINT: It's not electric vehicles, nuclear power, or wind energy).
Show Me How This Industry Could Explode!